Steven M Sanders

US Patent:

6743441, Jun 1, 2004

Filed:

Mar 15, 2002

Appl. No.:

10/098752

Inventors:

Steven W. Sanders - Salt Lake City UT
Charles D. Ebert - Salt Lake City UT

Assignee:

Watson Pharmaceuticals, Inc. - Corona CA

International Classification:

A61F 1302

US Classification:

424448, 424449, 424422, 424434

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7029694, Apr 18, 2006

Filed:

Nov 1, 2002

Appl. No.:

10/286381

Inventors:

Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00
A61F 13/02
A61K 15/16

US Classification:

424449, 424443, 424448

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

US Patent:

7081249, Jul 25, 2006

Filed:

Dec 8, 2003

Appl. No.:

10/731039

Inventors:

Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00

US Classification:

424449, 424448

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7081250, Jul 25, 2006

Filed:

Dec 8, 2003

Appl. No.:

10/731040

Inventors:

Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00

US Classification:

424449, 424448

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7081251, Jul 25, 2006

Filed:

Dec 8, 2003

Appl. No.:

10/731041

Inventors:

Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00

US Classification:

424449, 424448

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7081252, Jul 25, 2006

Filed:

Dec 8, 2003

Appl. No.:

10/731824

Inventors:

Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00

US Classification:

424449, 424448

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7087241, Aug 8, 2006

Filed:

Oct 7, 2005

Appl. No.:

11/246558

Inventors:

Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US

Assignee:

Watson Laboratories, Inc. - Salt Lake City UT

International Classification:

A61F 13/00
A61F 13/02
A61L 15/16

US Classification:

424449, 424448, 424434, 424435, 424422

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

US Patent:

7179483, Feb 20, 2007

Filed:

Aug 6, 2004

Appl. No.:

10/913019

Inventors:

Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US

Assignee:

Watson Pharmaceuticals, Inc. - Corona CA

International Classification:

A61F 13/00
A61F 13/02
A61L 15/16

US Classification:

424449, 424448, 424443

Abstract:

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.